Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination drug containing the following active pharmaceutical ingredients: **baclofen** (a GABA-B receptor agonist and skeletal muscle relaxant), **diazepam** (a benzodiazepine, anxiolytic and muscle relaxant), **clonazepam** (a benzodiazepine used for seizures and panic disorder), **trihexyphenidyl** (an anticholinergic used for Parkinson's disease), **tetrabenazine** (a VMAT2 inhibitor for hyperkinetic movement disorders), **gabapentin** (an anticonvulsant and neuropathic pain agent), **topiramate** (an anticonvulsant and migraine prophylactic, modulating voltage-gated ion channels and enhancing GABA activity), **lamotrigine** (an anticonvulsant inhibiting voltage-sensitive sodium channels), and **amitriptyline** (a tricyclic antidepressant inhibiting serotonin and norepinephrine reuptake). This combination covers a broad spectrum of neuropsychiatric and neuromuscular actions, including muscle relaxation, seizure control, movement disorder management, neuropathic pain, mood stabilization, and anticholinergic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on baclofen + diazepam + clonazepam + trihexyphenidyl + tetrabenazine + gabapentin + topiramate + lamotrigine + amitriptyline.